MET and cancer: Furthermore, we have found that SEMA3C is a secreted growth factor that can transactivate EGFR and MET signaling in other cancers such as renal, bladder, as well as glioblastoma, thus implicating SEMA3C as a potentially important driver of growth and survival for a broad spectrum of cancers in addition to prostate cancer.